OBJECTIVES: To examine the long-term effect of certolizumab pegol (CZP) on workplace and household productivity up to 4 years (216 weeks [wks]) in patients with active psoriatic arthritis (PsA), including patients with and without prior anti-TNF exposure. METHODS: RAPID-PsA (NCT01087788) was double-blind and placebo-controlled to Wk24, dose-blind to Wk48 and open-label to Wk216. Patients had active PsA and had failed ≥1 DMARD. Patients originally randomized to CZP (200mg Q2W or 400mg Q4W, following 400mg loading dose at Wks 0, 2, 4) continued their assigned dose in the open-label period. The validated arthritis-specific Work Productivity Survey (WPS), administered Q4W from baseline, assessed the impact of PsA on workplace and household productivity. A socio-professional module collected Q4W assessed caregiver burden. Descriptive statistics (LOCF imputation) in patients originally randomized to CZP (randomized set) are summarized over 216 wks. RESULTS: CONCLUSIONS: The initial improvements with CZP in workplace and household productivity and social participation were sustained long-term, for up to 4 years in PsA patients irrespective of prior anti-TNF exposure.